| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.12.24 | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | 126 | GlobeNewswire (Europe) | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| 08.12.24 | Agios Pharmaceuticals, Inc.: Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat | 73 | GlobeNewswire (Europe) | - ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia - - ENERGIZE-T is First Phase 3 Study to Demonstrate Efficacy... ► Artikel lesen | |
| 08.12.24 | C4 Therapeutics, Inc.: C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader | 92 | GlobeNewswire (Europe) | In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR)... ► Artikel lesen | |
| 08.12.24 | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | 64 | GlobeNewswire (Europe) | 52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median time to response 2.2 months with... ► Artikel lesen | |
| 08.12.24 | Affimed N.V.: Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients | 161 | GlobeNewswire (Europe) | The combination of acimtamig with AlloNK® demonstrated an overall response rate of 86% and complete response of 55% in 22 heavily pretreated patients with R/R cHL, who have exhausted all standard... ► Artikel lesen | |
| 08.12.24 | Regeneron Pharmaceuticals, Inc.: Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab | 54 | GlobeNewswire (Europe) | Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease control, as measured by lactate dehydrogenase... ► Artikel lesen | |
| 08.12.24 | Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ and Its Impact on Blood Cancer Treatment Decisions | 70 | GlobeNewswire (Europe) | New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies show depth of response at 10-6 provides more accurate assessment... ► Artikel lesen | |
| 08.12.24 | F. Hoffmann-La Roche Ltd: Five-year results confirm Roche's Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma | 554 | GlobeNewswire (Europe) | Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a positive trend in overall survival in favour of Polivy in combination with R-CHP for people with first-line diffuse... ► Artikel lesen | |
| 08.12.24 | Novartis Pharma AG: Longer-term data for Novartis Scemblix reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML | 718 | GlobeNewswire (Europe) | Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2% vs. 47.1%), meeting both ASC4FIRST 96-week key... ► Artikel lesen | |
| 08.12.24 | Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024 | 347 | GlobeNewswire (Europe) | MP0533 phase 1/2a dose escalation study continues with overall acceptable safety profile to date as well as initial antileukemic and pharmacodynamic activity
Clinical protocol amendment in process... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| D-WAVE QUANTUM | 4.915 |
| BAYER | 4.151 |
| NEL | 3.302 |
| NVIDIA | 3.024 |
| EVOTEC | 2.377 |
| TESLA | 1.869 |
| DEUTSCHE BANK | 1.788 |
| TUI | 1.698 |
| PLUG POWER | 1.618 |
| COMMERZBANK | 1.582 |
| DEUTSCHE LUFTHANSA | 1.542 |
| NOVO NORDISK | 1.402 |
| RENK GROUP | 1.205 |
| VOLKSWAGEN | 1.180 |
| BASF | 1.150 |
| KONTRON | 1.066 |
| NORDEX | 1.053 |
| RHEINMETALL | 1.017 |
| BYD | 995 |
| RWE | 965 |
| MERCEDES-BENZ | 956 |
| BIONTECH | 874 |
| DEUTSCHE TELEKOM | 811 |
| MICROSTRATEGY | 769 |
| THYSSENKRUPP | 756 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
